Latest Headlines

31. Collaborations Pharmaceuticals, Inc., Partners With Bausch + Lomb To Publish Research On Advancing AI Drug Development 10/7/2025

    Collaborations Pharmaceuticals, Inc. (CPI) has partnered with Bausch + Lomb to build and validate an array of artificial intelligence (AI) machine learning models with the goal of identifying new oral drugs that could reach the eye. 

32. New Drug Combination Offers Hope For Men With Advanced Prostate Cancer 10/7/2025

    A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.

33. MOLCURE Joins Forces With Boehringer Ingelheim To Discover And Develop Innovative Antibody Drugs For Multiple Targets Using Its AI-Driven Platform Technology 10/7/2025
34. Precision NeuroMed Granted FDA Orphan Drug Designation By U.S. FDA For Treatment Of Glioblastoma Multiforme (GBM) 10/7/2025

    Precision NeuroMed (PNM), a clinical-stage biotechnology company pioneering advanced drug delivery technologies for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational therapy for glioblastoma (GBM).

35. Algen Biotechnologies Announces Multi-Target Partnership To Advance AI-Powered Drug Discovery In Immunology With AstraZeneca 10/6/2025

    Algen Biotechnologies, a biotechnology company pioneering next-generation therapies using advanced CRISPR gene modulation and AI-driven drug discovery, today announced a multi-target partnership with AstraZeneca to accelerate the discovery of novel therapeutic targets in immunology.

36. Monash University Establishes Boston-Based Hub To Expedite Drug Discoveries And Innovations 10/3/2025

    In response to its accelerated success in the research commercialisation arena, Monash University has today announced the establishment of the Monash Boston Hub located in Boston, USA.

37. Elix, An AI Drug Discovery Company, And Tohoku University Enter Joint Research Agreement To Advance AI Drug Discovery 10/2/2025

    Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) and the Graduate School of Life Sciences at Tohoku University (Dean: Kouki Hikosaka / Headquarters: Miyagi; hereinafter “Tohoku University”) are pleased to announce the signing of a joint research agreement aimed at advancing drug discovery using AI technologies.

38. XenoSTART And Minerva Imaging Expand Partnership To Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform 10/2/2025

    The START Center for Cancer Research ("START"), its preclinical division XenoSTART, and Minerva Imaging today announced an expansion of their decade-long partnership to establish the industry's most comprehensive integrated platform for radiopharmaceutical drug development.

39. QuantHealth Secures Strategic Investment From Sanofi Ventures To Accelerate AI-Driven Clinical Trials 10/1/2025

    QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth’s efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30M.

40. Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation By U.S. FDA For The Treatment Of Alzheimer's Disease 10/1/2025

    Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease.